ANKE BIO(SZ:300009) 智通财经网·2025-11-11 10:58Core Viewpoint - Anke Bio (300009.SZ) has entered into a strategic cooperation with its affiliate, Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd., to exclusively distribute the PA3-17 injection product in Greater China after its market launch, enhancing its position in the CAR-T cell therapy sector [1][2] Group 1 - The PA3-17 injection is the world's first targeted CD7 autologous CAR-T cell therapy product approved for clinical trials, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies [1] - The product has been included in the breakthrough therapy list by the National Medical Products Administration (NMPA) and is currently in a critical Phase II clinical trial [1] - Boshengji plans to entrust Anke Bio with long-term cooperation for the sales and promotion of PA3-17 in the Greater China market, with a formal exclusive agency agreement to be signed after the product's market application submission [1] Group 2 - The exclusive agency cooperation aims to leverage the strengths of both companies, achieving synergistic development effects [2] - Through the exclusive agency model, the company can quickly introduce innovative drug products, filling existing gaps in the CAR-T cell therapy field and enriching its product matrix [2] - This partnership is expected to enhance the company's core competitiveness in the innovative drug market [2]